Table 1 Clinicopathological characteristics and HPV status of cervical pre-cancer, cancer patients and controls.
|  | Pathology | Number of samples | Total HPV + (HPV L1 Consensus) (n/%) | HPV16 Positive (n/%) | HPV18 Positive (n/%) | |||
|---|---|---|---|---|---|---|---|---|
Urine | Cervical scrape/Biopsy | Urine | Cervical scrape/ Biopsy | Urine | Cervical scrape/Biopsy | |||
Normal /Control | Â | 50 | 3(6%) | 4(8%) | 2(4%) | 2(4%) | 0 | 0 |
Pre-cancer | Â | 50 | 30 (60%) | 35(70%) | 28 (56%) | 32(64%) | 0 | 0 |
LSIL | 17 | 4 (8%) | 7(14%) | 4(8%) | 4(8%) | 0 | 0 | |
HSIL | 33 | 26 (52%) | 28 (56%) | 24 (48%) | 28(56%) | 0 | 0 | |
Cancer | Â | 50 | 40 (80%) | 36* (90%) | 37 (74%) | 34*(85%) | 2 (4%) | 2 (4%) |
Histopathological grading | WDSCC | 28 | 23(46%) | 16(40%) | 20 (40%) | 14(35%) | 0 | 0 |
MDSCC | 12 | 10 (20%) | 10(25%) | 10 (20%) | 10(25%) | 0 | 0 | |
PDSCC | 10 | 7 (14%) | 10 (25%) | 7 (14%) | 10(25%) | 0 | 0 | |
Clinical stage | Â | 50 | 45 (90%) | 46 (92%) | 40 (80%) | 42 (84%) | 0 | 0 |
Stage I | 10 | 10 (20%) | 8 (16%) | 8 (16%) | 8 (16%) | 0 | 0 | |
Stage II | 17 | 17 (34%) | 15 (30%) | 14 (28%) | 15 (30%) | 0 | 0 | |
Stage III | 18 | 15(30%) | 18 (36%) | 15 (30%) | 15 (30%) | 1 (2%) | 1 (2%) | |
Stage IV | 5 | 3 (6%) | 5 (10%) | 3 (6%) | 4 (8%) | 1 (2%) | 1 (2%) | |
